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Macrophages  (M~)  have  the  critical  function of presenting antigens in  a 
highly immunogenic form to responding antigen-specific T  and B cells in the 
initiation of immune responses (1, 2). In primary antibody responses to T-cell- 
dependent antigens in vitro, genetic restrictions in M~-lymphocyte interactions 
are not apparent (1-4).  By contrast, interactions between ~  and immune T 
cells  in  the  generation  and  functional expression of carrier-specific  murine 
helper T  cells in vitro  (5),  DNA-synthetic responses to antigens by immune 
guinea pig  (6,  7)  and murine  (8) T  lymphocytes, and expression of delayed 
hypersensitivity reactions in mice (9) are controlled by products of the I  region 
(or  its  equivalent)  of the  major  histocompatibility complex  (MHC)  of the 
species. The environment in which these T cells are first exposed to antigens 
has emerged as a  critical factor in the subsequent expression of the genetic 
restrictions (3,  4,  10). Thus, immune murine lymphocytes develop secondary 
plaque-forming cell  (PFC) responses preferentially when stimulated in vitro 
with antigen on M¢ syngeneic to the M~ used to immunize the spleen cells in 
vivo (3, 4).  These genetic restrictions are antigen-specific, they operate at the 
level of the immune T  cell,  and they are  controlled by products of the I-A 
subregion of the H-2 complex (3, 4, 11). 
The products of MHC-linked immune response (Ir) genes themselves may be 
involved  in  mediating  genetic  restrictions  in  M¢-T-cell  interactions.  For 
example, in guinea pigs, immune (nonresponder × responder)F1 T cells develop 
DNA-synthetic responses to antigens under the control of MHC-linked Ir gene(s) 
when the antigen is associated with responder, but not nonresponder, parental 
lVkb (6, 7). These observations led to the hypothesis that the Ir gene product is 
functionally expressed in M~, and nonresponder M~ lack this product and are 
therefore unable to present antigens in an immunogenic form to stimulate the 
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T  cells  (7).  Similar observations  have  recently  been  made  with  an  antigen 
under Ir gene control in delayed hypersensitivity responses in mice (12). 
The  antibody  response  of mice  to  the  terpolymer  of L-glutamic  acid6°4, - 
alanine3°-L-tyrosine 1°  (GAT)  is  controlled  by an  MHC-linked  Ir gene(s)  (13). 
Since allogeneic nonresponder MS  stimulate primary  PFC responses to GAT 
by  responder  lymphoid  cells  comparable  to  those  stimulated  by  syngeneic 
responder M~b (3, 4, 14), the defect in nonresponder mice does not appear to be 
expressed in the MS, but rather appears to be due to a preferential development 
of GAT-specific  suppressor  T  cells  (13,  15).  In  light  of the  aforementioned 
studies with guinea pigs indicating M~b localized Ir gene defects, the capacity 
of responder and nonresponder MS  to stimulate  responses to GAT by spleen 
cells from virgin and immune (responder x  nonresponder)F1 mice was investi- 
gated and is the subject of this communication. 
Materials and Methods 
Mice.  In experiments carried out at Harvard Medical School, C57BL/6 (B6) and DBA/1 (D1) 
mice were purchased from The Jackson Laboratory, Bar Harbor,  Maine; (C57BL/6  x  DBA/1)F1 
(B6  x  D1)F~  mice were bred in the Department of Pathology Animal Facility.  In experiments 
carried out at The Jewish Hospital, C57BL/10 (B10), D1, DBA/2 (D2), C3H/He (C3H),  (C57BL/10 
x  DBA/1)FI  [(B10  ×  D1)F1],  and  (C57BL/6  x  DBA/2)F~  [(B6  ×  D2)F~]  mice were bred in the 
Animal  Facility  in  the  Yalem  Building.  All  mice  were  maintained  on  laboratory  chow  and 
acidified-chlorinated water ad lib. and used at 10-20 wk of age. In a  single experiment, animals 
were sex and age matched. D1 mice are nonrespenders to GAT; all other mice are responders. 
Antigens.  GAT  (Miles Laboratories Inc.,  Elkhart,  Ind.),  mol wt ~45,000,  was prepared for 
use as antigen in culture (16),  for preparing GAT-M¢ (3), and for coupling to sheep erythrocytes 
for use as indicator cells in the PFC assay (16) as previously described. 
Culture System and Hemolytic Plaque Assay.  At Harvard Medical School, spleen cells at 7.5 
x  106 cells/ml in completely supplemented Eagle's minimal essential medium  containing 10% 
fetal calf serum  (Reheis Co., Inc., Kankakee, Ill.) and 10 mM N-2-hydroxyethylpiperazine-N'-2- 
ethane  sulfonic  acid  (Hepes)  (Hepes-MEM)  were  incubated  with  GAT-M~b  or  GAT  as  1-ml 
cultures in 16-mm wells of a  24-sample multiwell dish (FB-16-24TC; Linbro Chemical Co., New 
Haven,  Conn.). At the Jewish Hospital,  spleen cells at 107 cells/ml in completely supplemented 
MEM  lacking Hepes  were  incubated and  GAT-M(b or  GAT  as  1-ml  cultures in 35-ram dishes 
(3001;  Falcon  Plastics,  Div.  of BioQuest,  Oxnard,  Calif.).  After  incubation for  5  days  under 
Mishell-Dutton  conditions,  IgG  GAT-specific  PFC  responses  were  assayed  using  the  slide 
modification of the Jerne hemolytic plaque assay (16). 
Preparation of GAT-Mcb  and  Immunization  of Mice.  The  preparation  of  GAT-M¢  using 
peptone-induced peritoneal  exudate  has been described  in detail  previously  (3).  F~  mice were 
immunized by i.p. injection of 4 x  10  ~ of the appropriate GAT-M~ (bearing ~ 25 ng GAT]106 cells) 
or  10  or  100  /zg GAT  in a  mixture of magnesium-aluminum hydroxide  gel  (Maalox;  Win.  H. 
Rorer, Inc., Ft.  Washington, Pa.) and pertussis vaccine (Eli Lilly & Co., Indianapolis, Ind.) (16). 
Results 
Responder  x  nonresponder (B6  x  D1)F1 mice were immunized i.p. with 100 
/~g GAT in Maalox-pertussis; 79 days later,  spleen cells from these and virgin 
mice  were  assayed  for  development  of IgG  GAT-specific  PFC  responses  to 
responder  or  nonresponder  parental  GAT-M~  and  soluble  GAT  (Table  I). 
Virgin (B6  x  D1)F1 spleen cells developed comparable primary PFC responses 
to responder  (B6)  and nonresponder (D1)  GAT-M~b. A  mixture of B6 and D1 
GAT-M¢,  equal to twice the  number of parental  GAT-M~b alone,  stimulated 
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TABLZ  I 
Secondary PFC Responses to GAT by Responder  x Nonresponder (B6  x DI)F~ Spleen 
Cells Stimulated by Parental GAT-M(a 
(B6 x DI)F, 
spleen cells*  GAT-M~/culture 
Day 5 IgG GAT-specific PFC/culture~ 
B6-Mc#  DI-M<b  B6-M~§ +  DI-M4,  GAT~  1 
Virgin  2 x I04  593  585  518  818 
GAT-primed  4  x  104  255  60  383  383 
2  x  104  338  <10  270  - 
1 x  104  510  <10  548  - 
5 x I03  <I0  30  <10  - 
* (B6 x DI)F, mice were immunized 79 days previously by i.p.  injection  of 100/zg GAT  in Maalox-pertussis. 
Virgin or GAT-primed  (B6 x D1)F, spleen cells  at 7.5 x 10  ~  cells/culture  were incubated with the indicated GAT-M¢  or soluble 
GAT  in HEPES-MEM  as described in Materials and Methods. GAT-Mtb had ---2  ng GAT/10  ~  cells. 
§ Equal numbers of B6 and D1 GAT-M~  were added to these cultures making the total  number of GAT-M~b/culture  twice the 
number indicated. 
II  The optimal dose of  soluble GAT  was i /~g/culture  for virgin spleen cells  and 0.3 /zg/culture  for primed spleen cells. 
TABLE  II 
Secondary PFC Responses to GAT by Responder x Nonresponder (BIO  x DI)F, Spleen 
Cells Stimulated by Parental GAT-M~b 
(BIO ×  DI)F~ spleen  GAT-M~b/culture 
cells* 
Day 5 IgG GAT-specific PFC/culture* 
BI0-M&  D1-M~b  C3H-M¢  5 p~ GAT 
Virgin  7  ×  104  150  180  210 
5  x  104  250  250  250  300 
GAT-primed  7  x  104  380  50  <10 
5  x  104  300  80  50  380 
B10 GAT-M~b primed  7  ×  10  ~  270  <10  <10 
5 x  10"  370  <10  <10  270 
D1 GAT-M~, primed  7  ×  10  ~  40  380  <I0 
5  x  10  ~  70  140  <10  300 
* (BI0 x  D1)F, mice were immunized 28 days previously by i.p. injection of 10 ~g GAT in Maalox-pertussis (GAT-primed), or 4 x 
10  ~ of the indicated M~b bearing ---25 ng of GAT/10  ~ cells. At culture initiation these spleen cells had <25 IgG GAT-specific PFC/ 
l0  T cells. 
Virgin or GAT-primed (B10 x  D1)F, spleen cells at 107 cells/culture were incubated with the indicated GAT-M~, or soluble GAT 
in MEM. GAT-Mcb had 52 ng GAT/10  s cell. 
(B6  ×  D1)F,  spleen cells, by contrast, developed secondary PFC responses to 
responder (B6) GAT-IVI~ and soluble GAT, but not to nonresponder (D1) GAT- 
M~.  Mixtures of equal numbers of B6 and D1 GAT-M6-stimulated responses 
comparable to those stimulated by the same number of B6  GAT-Mqb alone, 
except at the lowest numbers tested, where 5  x  103 B6 GAT-M~  also failed to 
stimulate a response. These data with mixtures of B6 and D1 M~b indicate that 
the failure of immune F, spleen cells to respond to the nonresponder D1 GAT- 
M& alone is not due to a nonspecific suppressive mechanism initiated by these 
M~. 
In the next experiments, responder × nonresponder (B10 × D1)F, mice were 
immunized i.p.  with 10  /~g GAT in Maalox-pertussis, or responder or nonre- 
sponder parental GAT-Mqb; 28  days later, spleen cells from these and virgin 
mice  were  assayed for  development of IgG  GAT-specific PFC  responses  to 
parental B10 and D1  GAT-M~b, third party C3H  GAT-M~, and soluble GAT 
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all  GAT-MS  and  soluble  GAT.  The  GAT-primed F1  spleen cells  developed 
secondary responses to responder B10 GAT-MS and soluble GAT, but failed to 
respond to  nonresponder D1  or third party  C3H  GAT-MS.  Identical results 
were observed in responses of F1 spleen cells primed with responder B10 GAT- 
MS.  By  contrast,  F,  spleen  cells  primed  with  nonresponder  D1  GAT-MS 
developed secondary responses with D1 GAT-MS  and soluble GAT, but failed 
to respond to third party C3H or responder B10 GAT-MS. A preliminary study 
using responder x  responder (B6 x  D2)F~ mice immunized with GAT indicates 
that these spleen cells develop secondary PFC responses after stimulation with 
either B10 or D2 GAT-MS, but fail to respond to third party C3H GAT-MS. 
Discussion 
These  experiments illustrate  three major points concerning the  ability of 
spleen cells from virgin and immune (responder  x  nonresponder)F1 mice to 
develop PFC responses after  stimulation with GAT or parental  GAT-M~b in 
vitro.  First,  virgin  F1  spleen  cells  develop comparable  primary  IgG  GAT- 
specific  PFC  responses  after  stimulation with  either  parental  or  unrelated 
third party GAT-M~. Second, spleen cells from F1 mice immunized with either 
parental GAT-M~b develop secondary responses in vitro to the GAT-M~b used 
for immunization in vivo. These results are consistent with previous observa- 
tions that spleen cells from mice immunized with syngeneic or allogeneic GAT- 
M~ develop secondary responses in vitro to GAT-M~b that are syngeneic at the 
I-A subregion of the H-2 complex with the M¢ used for priming (3, 4,  11). In 
many of these experiments, M~b from nonresponder mice induced these genetic 
restrictions  in  spleen cells  of homozygous responder mice  (3,  4,  11). These 
observations and others  (14), led to the earlier conclusion that the defect in 
nonresponder mice, in the case of GAT, was not in the M~b. 
The third observation is that spleen cells from F1 mice immunized with GAT 
develop secondary responses  in  vitro only when  stimulated with responder 
parental GAT-M¢. This indicates that in virgin (respender x  nonrespender)F~ 
mice immunized with GAT, which would of necessity be presented by F1 M~b, 
the responder component of the F1 MS predominates and selectively primes a 
population  of F1  T  cells  capable  of being  activated  subsequently  only  by 
respender GAT-MS in culture. These results imply that Ir-gene function may 
be expressed in murine MS, and they are in agreement with observations in 
proliferative  responses with  F1  guinea  pig  lymphocytes  (6,  7)  and  delayed 
hypersensitivity responses in F~ mice (12). 
We must now resolve the contradiction between;  (a)  the ability of nonre- 
sponder GAT-M~ to stimulate primary responses in both homozygous responder 
and heterozygous (responder x  nonresponder)F1 mice, and to prime these mice 
such that secondary responses are restricted to the nonresponder GAT-M~b, and 
(b)  the  failure  of GAT-primed  F1  mice  to  develop secondary  responses  to 
nonresponder GAT-M~b. It  is  possible that  Ir-gene function is  expressed in 
murine M~  and that  nonresponder M~b  express  some, but not all,  of these 
functions with regard to GAT. Thus, only in certain circumstances (e.g. the F~ 
animal), would these differences be revealed. The expression of only one set of 
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spender ×  nonresponder)F, may impose restrictions on the interactions among 
F, M~b and different subsets of T cells during priming with GAT. Alternatively, 
if, as demonstrated in guinea pigs  (17),  F, mice possess distinct subsets of T 
cells, each capable of interacting with one but not the other parental Me, it is 
possible  that  helper  T  cells  specific  for  responder  GAT-M~  are  primed  by 
injection of GAT, whereas helper T cells capable of responding to nonresponder 
GAT-M~b  are  not  primed.  This  hypothesis  is  supported  by  these  previous 
observations  in  nonresponder  mice:  (a)  GAT  induces  suppressor,  but  not 
radioresistant helper T cells (13, 14, 18); (b) radioresistant GAT-specific helper 
T  cells  can be  induced by  injection of nonresponder mice with  GAT-M~ or 
GAT-MBSA (13,  18); and,  (c) injection of GAT not only induces suppressor T 
cells, but also prevents the development of GAT-specific helper T  cells after 
injection of GAT-MBSA (13). 
Summary 
The development of IgG L-glutamic acid6°-L-alanine3°-L-tyrosine  '° (GAT)-spe- 
cific plaque-forming cell responses in vitro by virgin and immune (responder x 
nonresponder)F, spleen cells after stimulation with responder and nonresponder 
parental  GAT-macrophages  (M~b) was  investigated.  Virgin  F,  spleen  cells 
developed comparable primary responses to both parental GAT-M&.  By con- 
trast,  F,  spleen cells from mice immunized with GAT or responder parental 
GAT-M& developed secondary responses after stimulation with only responder 
parental  GAT-M~.  Spleen cells from F~  mice immunized with nonresponder 
parental GAT-M~b developed secondary responses to these GAT-M~b, but failed 
to respond to respender parental GAT-M~. These results are discussed in the 
context of genetic restrictions regulating M~b-T-cell  interactions in secondary 
antibody responses and the possible expression of Ir-gene function in M~b. 
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